Physiologically based pharmacokinetic modelling and in vivo [I]/Ki accurately predict P‐glycoprotein‐mediated drug‐drug interactions with dabigatran etexilate
Physiologically based pharmacokinetic modelling and in vivo [I]/Ki accurately predict P‐glycoprotein‐mediated drug‐drug interactions with dabigatran etexilate
复制标题
基于生理学的药代动力学模型和体内 [I]/Ki 准确预测 P 糖蛋白介导的达比加群酯的药物间相互作用
作者：
Yuansheng Zhao;Zhe
基于体外抑制效力(Ki)的P-糖蛋白(P-gp)介导的药物-药物相互作用(DDiS)的预测受到抑制效力的显著差异的阻碍。在这项研究中，基于体内的[I]/KI值被用来通过基于生理的药代动力学(PBPK)模型来预测P-gp底物达比卡特兰乙酯(DABE)的DDI风险。
In vitro inhibitory potency (Ki)‐based predictions of P‐glycoprotein (P‐gp)‐mediated drug‐drug interactions (DDIs) are hampered by the substantial variability in inhibitory potency. In this study, in vivo‐based [I]/Ki values were used to predict the DDI risks of a P‐gp substrate dabigatran etexilate (DABE) using physiologically based pharmacokinetic (PBPK) modelling.
DOI：
--
发表时间：
1999-08
期刊：
Drug metabolism and disposition: the biological fate of chemicals
影响因子：
--
作者：
M. Cvetkovic;B. Leake;M. Fromm;G. Wilkinson;R. Kim
通讯作者：
M. Cvetkovic;B. Leake;M. Fromm;G. Wilkinson;R. Kim